(People's Daily Health Client Liu Yingqi) According to the documents of the Hong Kong Stock Exchange on the evening of June 27, Amic submitted a listing application and planned to raise funds for investment, acquisition and licensing arrangements, development and expansion of product pipeline, expansion Global layout, marketing and brand building, as well as supplementing working capital, etc. As of the close of trading on June 27, Amic’s A shares were quoted at 585 yuan per share, with a market value of 126.571 billion yuan.
Hong Kong Stock Exchange Picture
People's Daily Health Client noted that this is the second time Amic has submitted a listing application to the Hong Kong Stock Exchange after expanding its product pipeline portfolio and multi-line layout. Amic was listed on the Shenzhen Stock Exchange GEM in September 2020. On July 23, 2021, it submitted to the China Securities Regulatory Commission the company’s proposed issuance of overseas listed foreign shares (H shares) and applied for listing on the Hong Kong Stock Exchange. Co., Ltd.’s main board listing application materials subsequently “invalidated”. This is Aimeike’s “second submission” to the Hong Kong Stock Exchange. If successfully listed this time, it is expected to become the first "A+H" listed medical aesthetics company in China.
The domestic medical beauty market may reach 300 billion yuan in 2022, with light medical beauty occupying half of the country
According to data from the Qianzhan Industry Research Institute, the scale of China's medical beauty market will continue to grow from 2018 to 2021, reaching approximately 227.4 billion yuan in 2021, compared with Growth in 2020 was 15.10%. According to the "Gengmei 2021 Medical Aesthetics Industry White Paper" released by genmeiAPP, it is predicted that China's medical aesthetics market will still maintain rapid growth in 2022, with a growth rate of more than 16%, and the market size may reach 264.3 billion yuan.
China’s medical aesthetics market size from 2018 to 2022 (unit: 100 million yuan)
Compared with medical aesthetics that require surgery, non-surgical light medical aesthetics is safer, more flexible, and has a shorter recovery period, becoming more and more popular The choice for beauty lovers. According to data from New Oxygen 's "2021 Medical Beauty Industry White Paper", among medical beauty projects in 2021, the market size of light medical beauty will account for 49.2%, accounting for half of the country.
Light medical beauty promotes the continued growth of hyaluronic acid and other industries. Amic hyaluronic acid products account for more than 98% of its revenue
The rise of light medical beauty has driven the development of hyaluronic acid and other industries. In 2020, the industry scale has approached 5 billion yuan. According to F According to Jost & Sullivan's forecast, the market size of the hyaluronic acid industry will be close to 8 billion yuan in 2022, an increase of nearly 27% compared with 2021. In 2020, China's botulinum toxin market size is close to 4 billion yuan, and it may exceed 6 billion yuan in 2022, maintaining a high growth rate.
According to the Frost & Sullivan Report, Amic is the largest supplier of dermal fillers based on hyaluronic acid in China in terms of sales volume in 2021, with a market share of 39.2%. According to the same source, Amic is the second largest supplier of hyaluronic acid-based dermal fillers in China in terms of sales in 2021, with a market share of 21.3%, and is also the largest hyaluronic acid-based dermal filler supplier among all domestic companies in China. Acid-based dermal filler supplier with a market share of 58.9%. As of the end of 2021, Amic's products have been adopted by more than 4,400 medical institutions.
According to the annual report of Amic, from 2019 to 2021, Amic’s revenue increased from 558 million yuan to 1.448 billion yuan, and its net profit increased from 298 million yuan to 954 million yuan during the same period. In the past three years, Amic's gross profit margins have reached 91.7%, 91.4%, and 93.3% respectively. During the reporting period, Amic's dermal filler products based on hyaluronic acid (hyaluronic acid) accounted for more than 98% of total revenue.
With 7 medical beauty products, Amic is expanding its product pipeline and sprinting to become the first "A+H" medical beauty product
As of the latest practical date, Amic currently has seven products that have been awarded the third place by the State Food and Drug Administration Products similar to medical device registration certificate include 5 hyaluronic acid-based dermal fillers, 1 poly-L-lactic acid-based dermal filler and 1 PPDO facial implant line product.
Regarding the domestic hyaluronic acid market, according to the analysis of snowball : From the perspective of the internal market structure, there are currently more than 60 types of filler hyaluronic acid in China. They are relatively homogeneous, and internal competition will become increasingly fierce, with the possibility of explosive products. The sex is getting smaller and smaller, and the marginal effect of product substitution is decreasing. Realizing that hyaluronic acid dermal filler products account for a large proportion, Amic is expanding its product pipeline portfolio.In May, Amic announced that the company had signed a distribution cooperation framework agreement with South Korea's Huons Bio Pharma Co. Ltd., agreeing to introduce its botulinum toxin products through R&D registration and serve as its only designated legal distributor within the agreed distribution area. Carry out import and distribution of products.
breaks the single-product situation through multi-line layout. Whether Amic can seize market share from the fierce market competition still requires continued attention.
